Brentuximab vedotin use in a jaundiced case with resistant Hodgkin lymphoma

被引：0
|
作者：
Semra Paydas
Ali Ogul
Cem Irili
Serkan Gokcay
机构：
[1] Cukurova University Faculty of Medicine,Department of Medical Oncology
来源：
Annals of Hematology | 2016年 / 95卷
关键词：
Neuropathy; Peripheral Neuropathy; Dose Adjustment; Hodgkin Lymphoma; Bendamustine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：145 / 146
页数：1
相关论文
共 50 条
  • [31] Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
    Salihoglu, A.
    Elverdi, T.
    Karadogan, I.
    Paydas, S.
    Ozdemir, E.
    Erdem, G.
    Karadurmus, N.
    Akyol, G.
    Kaynar, L.
    Yegin, Z. A.
    Sucak, G.
    Ozkocaman, V.
    Topcuoglu, P.
    Ozcan, M.
    Birtas, E.
    Goker, H.
    Baslar, Z.
    Ferhanoglu, B.
    ANNALS OF HEMATOLOGY, 2015, 94 (03) : 415 - 420
  • [32] Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma
    Makita, Shinichi
    Maruyama, Dai
    Tobinai, Kensei
    ONCOTARGETS AND THERAPY, 2020, 13 : 5993 - 6009
  • [33] Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
    Siddiqi, Tanya
    Thomas, Sandra H.
    Chen, Robert
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 : 79 - 85
  • [34] Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era
    Graf, Solomon A.
    Gopal, Ajay K.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2014, : 151 - 157
  • [35] Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma
    Zsuzsa, Molnar
    Imre, Pinczes Laszlo
    Klara, Piukovics
    Ildiko, Istenes
    Krisztina, Wolf
    Zoltan, Csukly
    Arpad, Szomor
    Arpad, Illes
    Zsofia, Miltenyi
    ORVOSI HETILAP, 2017, 158 (41) : 1630 - 1634
  • [36] THE COST-EFFECTIVENESS OF BRENTUXIMAB VEDOTIN IN HODGKIN LYMPHOMA IN SWEDEN
    Engstrom, A.
    VALUE IN HEALTH, 2014, 17 (07) : A639 - A639
  • [37] The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Senter, Peter D.
    Sievers, Eric L.
    NATURE BIOTECHNOLOGY, 2012, 30 (07) : 631 - 637
  • [38] Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma
    Arora, Anubha
    Bhatt, Vijaya Raj
    Liewer, Susanne
    Armitage, James O.
    Bociek, R. Gregory
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (04) : 361 - 364
  • [39] Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: A case report
    Urru S.A.M.
    Mariotti E.
    Carta P.
    Massidda S.
    Marcias M.
    Murru R.
    Sanna P.
    Angelucci E.
    Drugs in R&D, 2014, 14 (1) : 9 - 11
  • [40] The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Peter D Senter
    Eric L Sievers
    Nature Biotechnology, 2012, 30 : 631 - 637
12345